A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE007 (JPN) · Dr. Dubois
consented 2023-07-11
AEs
3
Serious
1
Dropout signal
–
Adverse events
severe
serious
assessed
Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-01-14 (study day 171); relationship: not assessed; serious criteria: hospitalization
mild
assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-01-27 (study day 184); relationship: not assessed
moderate
assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2024-03-03 (study day 220); relationship: not assessed
Data queries
No data queries.